Recently, several studies have demonstrated that in vitro treatment of cancer cells with C225 can downregulate the production of angiogenic factors such as VEGF, interleukin-8, or basic fibroblast growth factor and that in vivo inhibition of EGF-R results in growth inhibition and reduction in microvessel density accompanied by decreases in angiogenic factor expression (Petit et al, 1997; Perrotte et al, 1999; Bruns et al, 2000; Ciardiello et al, 2000). This evidence concerns the gene VEGFA and cancer.